Whey and soy protein supplements changes body composition in patients with crohn’s disease undergoing azathioprine and anti-TNF-alpha therapy;suplementos de proteÍna de suero y soya cambia la composiciÓn corporal en los pacientes con enfermedad de crohn sometidos con azatioprina y anti-TNF-alfa terapias

Nutricion Hospitalaria

Volumn 31, Issue 4, 2015, Pages 1603-1610

  Machado, Júlia Figueiredo ^a   Oya, Vanessa ^a   Coy, Cláudio Saddy Rodrigues ^a   Morcillo, André Moreno ^a   Severino, Silvana Dalge ^a   Wu, Chao ^b   Sgarbieri, Valdemiro Carlos ^a   dos Santos Vilela, Maria Marluce ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

^b Hilmar Cheese Company   (United States)

Author keywords

Body composition; Crohn s disease; Soy protein; Whey protein

Indexed keywords

AZATHIOPRINE; IMMUNOSUPPRESSIVE AGENT; SOYBEAN PROTEIN; TUMOR NECROSIS FACTOR; WHEY PROTEIN;

ADULT; ANTAGONISTS AND INHIBITORS; BODY COMPOSITION; CONTROLLED STUDY; CROHN DISEASE; DIET THERAPY; DIETARY SUPPLEMENT; DRUG EFFECTS; FEMALE; HUMAN; MALE; MIDDLE AGED; NUTRITIONAL STATUS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AZATHIOPRINE; BODY COMPOSITION; CROHN DISEASE; DIETARY SUPPLEMENTS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NUTRITIONAL STATUS; SOYBEAN PROTEINS; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; WHEY PROTEINS;

EID: 84925359672     PISSN: 02121611     EISSN: 16995198     Source Type: Journal    
DOI: 10.3305/nh.2015.31.4.8362     Document Type: Article

References (30)

1. Baumgart DC, Sandborn WJ. Crohn’s disease. Lancet 2012;380(9853):1590-605.
2. Peyrin-Biroulet L, Billioud V, D’Haens G, Panaccione R, Feagan B, Panés J, et al. Development of the Paris definition of early Crohn’s disease for disease-modification trials: results of an international expert opinion process. Am J Gastroenterol 2012;107(12):1770-6.
3. Thia K, Faubion WA Jr, Loftus EV Jr, Persson T, Persson A, Sandborn WJ. Short CDAI: development and validation of a shortened and simplified Crohn’s disease activity index. Inflamm Bowel Dis 2011;17(1):105-11.
4. Peyrin-Biroulet L, Reinisch W, Colombel JF, Mantzaris GJ, Kornbluth A, Diamond R, et al. Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn’s disease in the SONIC trial. Gut 2014;63(1):88-95.
5. Sousa Guerreiro C, Cravo M, Costa AR, Miranda A, Tavares L, Moura-Santos P, et al. A comprehensive approach to evaluate nutritional status in Crohn’s patients in the era of biologic therapy: a case-control study. Am J Gastroenterol 2007;102(11):2551-6.
6. Steed H, Walsh S, Reynolds N. A brief report of the epidemiology of obesity in the inflammatory bowel disease population of Tayside, Scotland. Obes Facts 2009;2(6):370-2.
7. Boutros M, Maron D. Inflammatory bowel disease in the obese patient. Clin Colon Rectal Surg 2011;24(4):244-52.
8. Karagiannides I, Pothoulakis C. Obesity, innate immunity and gut inflammation. Curr Opin Gastroenterol 2007;23(6):661-6.
9. Blain A, Cattan S, Beaugerie L, Carbonnel F, Gendre JP, Cosnes J. Crohn’s disease clinical course and severity in obese patients. Clin Nutr 2002;21(1):51-7.
10. Hass DJ, Brensinger CM, Lewis JD, Lichtenstein GR. The impact of increased body mass index on the clinical course of Crohn’s disease. Clin Gastroenterol Hepatol 2006;4(4):482-8.
11. Aoyama T, Fukui K, Takamatsu K, Hashimoto Y, Yamamoto T. Soy protein isolate and its hydrolysate reduce body fat of dietary obese rats and genetically obese mice (yellow KK). Nutrition 2000;16(5):349–54.
12. Frestedt JL, Zenk JL, Kuskowski MA, Ward LS, Bastian ED. A whey-protein supplement increases fat loss and spares lean muscle in obese subjects: a randomized human clinical study. Nutr Metab (Lond) 2008;5:8.
13. Baer DJ, Stote KS, Paul DR, Harris GK, Rumpler WV, Clevidence BA. Whey protein but not soy protein supplementation alters body weight and composition in free-living overweight and obese adults. J Nutr 2011;141(8):1489-94.
14. Gilbert JA, Bendsen NT, Tremblay A, Astrup A. Effect of proteins from different sources on body composition. Nutr Metab Cardiovasc Dis 2011;21(2):B16-31.
15. Davanço T, Oya V, Coy CSR, Leal RF, de Ayrizono MLS, Sgarbieri VC et al. Nutritional supplementation assessment with whey proteins and TGF-β in patients with Crohn’s disease. Nutr Hosp 2012; 27(4):1286-92.
16. Moreno YF, Sgarbieri VC, Da Silva MN, Toro AA, Vilela MM. Features of Whey Protein Concentrate Supplementation in Children with Rapidly Progressive HIV Infection. J Trop Pediatr 2006;52(1):34-38.
17. de Aguilar-Nascimento JE, Prado Silveira BR, Dock-Nascimento DB. Early enteral nutrition with whey protein or casein in elderly patients with acute ischemic stroke: a double-blind randomized trial. Nutrition 2011;27(4):440-444.
18. Frisancho AR. New norms of upper limb fat and muscle areas for assessment of nutritional status. Am J Clin Nutr 1981;34(11):2540-5.
19. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn’s disease activity index. National Cooperative Crohn’s Disease Study. Gastroenterology 1976;70(3):439-444.
20. Beattie RM, Schiffrin EJ, Donnet-Hughes A, Huggett AC, Domizio P, MacDonald TT, et al. Polymeric nutrition as the primary therapy in children with small bowel Crohn’s disease. Aliment Pharmacol Ther 1994;8(6):609-15.
21. Fell JM, Paintin M, Arnaud-Battandier F, Beattie RM, Hollis A, Kitching P, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn’s disease. Aliment Pharmacol Ther 2000;14(3):281-9.
22. Solem CA, Loftus EV Jr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, histologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005;11(8):707-12.
23. Chamouard P, Richert Z, Meyer N, Rahmi G, Baumann R. Diagnostic value of C-reactive protein for predicting acti vity level of Crohn’s disease. Clin Gastroenterol Hepatol 2006;4(7):882-7.
24. Instituto Brasileiro de Geografia e Estatística – IBGE: Pesquisa de orçamentos familiares 2008-2009: antropometria e estado nutricional de crianças, adolescentes e adultos no Brasil. IBGE. Rio de Janeiro; 2010.
25. Bertin B, Desreumaux P, Dubuquoy L. Obesity, visceral fat and Crohn’s disease. Curr Opin Clin Nutr Metab Care 2010;13(5):574-80.
26. Filippi J, Al-Jaouni R, Wiroth JB, He´buterne X, Schneider SM. Nutritional deficiencies in patients with Crohn’s disease in remission. Inflamm Bowel Dis 2006;12(3):185-91.
27. Vagianos K, Bector S, McConnell J, Bernstein CN. Nutrition assessment of patients with inflammatory bowel disease. J Parenter Enteral Nutr 2007;31(4):311-9.
28. Hwang C, Ross V, Mahadevan U. Micronutrient deficiencies in inflammatory bowel disease: from A to zinc. Inflamm Bowel Dis 2012;18(10):1961-81.
29. Zallot C, Quilliot D, Chevaux JB, Peyrin-Biroulet C, Guéant-Rodriguez RM, Freling E, et al. Dietary beliefs and behavior among inflammatory bowel disease patients. Inflamm Bowel Dis 2013;19(1):66-72.
30. Davanço T, Silva LB, Sampaio Kde L, Coy CS, Vilela MM, Pinto EA. Acceptability of an Alimentary Supplement of Whey-Protein Concentrate and TGF-β in Patients with Crohn’s Disease. ISRN Nutr 2013;2013:947865.